Previous 10 | Next 10 |
Children in LT-001 treated after SMA symptom onset maintained or achieved additional milestones up to 7.5 years post one-time intravenous infusion All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including ind...
New approval based on TADPOLE trial showing overall response rate (ORR) of 47% and median progression-free survival (mPFS) of 20.1 months for Tafinlar + Mekinist compared to 11% ORR and 7.4 months mPFS for standard of care 1 ,2 Approval also received for liquid for...
DURHAM, N.C., March 16, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the issuance and sale in the Company’s previously announced registered direct offering of an aggregate of (i) 5,042,017 shares ...
2023-03-14 08:48:24 ET Novan ( NASDAQ: NOVN ) has entered into definitive agreements for the issuance and sale in a registered direct offering of an aggregate of 5.04M shares and warrants to purchase up to 5.04M shares at an effective combined purchase price of $1.19/share . ...
2023-03-14 08:34:23 ET GitLab ( GTLB ) -30% on Q4 earnings release . Cingulate ( CING ) -11% . 9 Meters Biopharma ( NMTR ) -9% after proposes to raise $5M in stock offering . BigBear.ai ( BBAI ) -9% on Q4 earnings release . B...
DURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that Paula Brown Stafford, President and Chief Executive Officer of Novan, will present at the virtual Oppenheimer 33 rd Annual Healthcare Confer...
2023-03-14 08:06:11 ET Novan ( NASDAQ: NOVN ) entered into definitive agreements for the issuance and sale in a registered direct offering of 5.04M shares and warrants at an effective combined purchase price of $1.19/share and associated common warrant. Warrants will ...
DURHAM, N.C., March 14, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has entered into definitive agreements for the issuance and sale in a registered direct offering of an aggregate of (i) 5,042,017 shares of i...
– Novan is a fully integrated pharmaceutical company with proven capabilities across drug development through to commercialization – – EPI Health adopts Novan corporate branding, creating unified identity in advance of potential commercial launch of berd...
2023-03-07 08:37:46 ET Dermatology drug developer Novan ( NASDAQ: NOVN ) announced Tuesday that the FDA accepted its New Drug Application (NDA) for berdazimer gel, 10.3%, as a treatment for viral infection, molluscum contagiosum. The agency has granted January 05, 2024, as...
News, Short Squeeze, Breakout and More Instantly...
– The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novan’s assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15 million in debtor-in-possession financing – – Progression toward...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company’s 2023 Annual Meeting of Stockholders (“ASM”) being held on Tuesday, June 6...
– Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum – – Process to explore a sale or out-license of commercial assets or other business transaction continues – – Continued progress ...